Marie Chambers
Adult Health · Centerville, OHNPI 1063538783
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,407 of the $134,202 with a category attached, or 69.6%. 21 manufacturers reported payments, led by AbbVie at 46.1% of the total. Among adult health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $225.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$62K
- Lundbeck LLC$33K
- Impel Pharmaceuticals Inc.$12K
- Biohaven Pharmaceuticals, Inc.$11K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Pfizer$5K
- plus $5K from 15 others
What the payments were for
- Consulting fees$21,84016%
- Speaking & faculty fees$93,40770%
- Travel & lodging$8,1856%
- Food & beverage$10,6258%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 204 | $61,921 |
| Lundbeck LLC | 142 | $33,114 |
| Impel Pharmaceuticals Inc. | 42 | $11,863 |
| Biohaven Pharmaceuticals, Inc. | 50 | $10,861 |
| Biohaven Pharmaceutical Holding Company Ltd. | 31 | $5,683 |
| Pfizer | 34 | $5,266 |
| Impel Pharmaceuticals LLC | 11 | $3,736 |
| Lilly USA, LLC | 16 | $393 |
| Amgen | 28 | $300 |
| Teva Pharmaceuticals USA, Inc. | 11 | $279 |
| Tonix Medicines, Inc. | 2 | $163 |
| Supernus Pharmaceuticals, Inc. | 11 | $120 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $96 |
| Bayer | 1 | $81 |
| Otsuka America Pharmaceutical, Inc. | 1 | $77 |
| Upsher-smith Laboratories LLC | 3 | $74 |
| AstraZeneca | 1 | $74 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$50,721
- VYEPTI$30,040
- NURTEC ODT$20,103
- QULIPTA$19,373
- Trudhesa$14,655
- ZEMBRACE SYMTOUCH$139
- TOSYMRA$139
- ZAVZPRET$114
- AJOVY$106
How this compares
$134,202 in reported general payments places this provider in the 95th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 230 | $267,512 |
| QuliptaAtogepant | 168 | $193,851 |
| Nurtec OdtRimegepant Sulfate | 136 | $166,166 |
| Emgality PenGalcanezumab-Gnlm | 126 | $93,089 |
| Aimovig AutoinjectorErenumab-Aooe | 76 | $62,362 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 48 | $45,676 |
| ReyvowLasmiditan Succinate | 24 | $17,189 |
| Almotriptan Malate | 13 | $2,495 |
| Acetazolamide ErAcetazolamide | 15 | $1,912 |
| Naproxen Sodium | 22 | $1,637 |
| Diclofenac Potassium | 31 | $1,077 |
| Naratriptan Hcl | 19 | $846 |
| Hydroxyzine Hcl | 43 | $746 |
| RizatriptanRizatriptan Benzoate | 53 | $727 |
| Topiramate | 113 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $61,921 | $461,362398 claims |
| PfizerNurtec Odt | $5,266 | $166,166136 claims |
| Lilly USA, LLCReyvow | $393 | $17,18924 claims |
| Upsher-smith Laboratories LLCTopiramate | $74 | $640113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,184 adult health providers in Ohio.
Other adult health in Centerville
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Susan FlickCleveland$131K
- Teresa ShafferBoardman$102K
- Jesse McClainYoungstown$79K
- Lucretia LongColumbus$76K
- Marybeth RivardColumbus$41K
- Mary Pat BartoszekCincinnati$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.